Phosphatase Dysregulation in Cancer: Signaling Pathways and Therapeutic Opportunities

Abstract

Phosphatases are increasingly recognized as critical regulators of cancer biology, with important roles in both tumor cells and the tumor immune microenvironment (TIME). These enzymes modulate intracellular signaling pathways that control tumor growth, immune evasion, and metastasis. Although phosphatases were once considered undruggable, recent advances have highlighted their therapeutic potential. Despite growing evidence, phosphatases remain underexplored as drug targets, with no approved therapies to date. This review presents an in-depth overview of phosphatase classification based on catalytic domain similarities and explores their diverse functions as tumor suppressors, oncogenic drivers, or context-dependent regulators. We describe how phosphatases such as PTPN6, PTPN22, and DUSPs regulate key pathways like RAS/MAPK and PI3K/AKT in both tumor and immune cells. Additionally, we discuss the role of phosphatases in shaping the tumor microenvironment through exosome secretion. This review highlights current therapeutic strategies, including small molecules and antibodies, and their synergistic effects with kinase inhibitors and immune checkpoint blockade. By summarizing recent advances, this paper underscores the need for deeper mechanistic insights into phosphatase function in cancer and immunity. Understanding these mechanisms will be key to unlocking their potential as novel therapeutic targets in oncology.

Keywords

non-receptor protein tyrosine phosphatases / signal transduction / therapeutics / tumor microenvironment / tumor promoter / tumor suppressor

References

[1] P. Cohen, “The Regulation of Protein Function by Multisite Phosphorylation–A 25 Year Update,” Trends in Biochemical Sciences 25, no. 12 (2000): 596–601.

[2] J. M. Drake, J. K. Lee, and O. N. Witte, “Clinical Targeting of Mutated and Wild-Type Protein Tyrosine Kinases in Cancer,” Molecular and Cellular Biology 34, no. 10 (2014): 1722–1732.

[3] S. M. Stanford and N. Bottini, “Protein Tyrosine Phosphatases in Tumor Progression and Metastasis: Promoter or Protection?,” Nature Reviews Drug Discovery 22, no. 4 (2023): 273–294.

[4] C. V. Ferreira-Halder, S. P. Clerici, A. V. S. Faria, P. F. S. Oliveira, H. G. Cordeiro, and E. Akagi, “Protein Tyrosine Phosphatases in Tumor Progression and Metastasis,” in Tumor Progression and Metastasis (IntechOpen, 2020): 1–21, https://doi.org/10.5772/intechopen.87963.

[5] I. M. Stromnes, C. Fowler, C. C. Casamina, et al., “Abrogation of SRC Homology Region 2 Domain-Containing Phosphatase 1 in Tumor-Specific T Cells Improves Efficacy of Adoptive Immunotherapy by Enhancing the Effector Function and Accumulation of Short-Lived Effector T Cells In Vivo,” Journal of Immunology 189, no. 4 (2012): 1812–1825.

[6] V. N. Korotchenko, M. Saydmohammed, L. L. Vollmer, et al., “In Vivo Structure–Activity Relationship Studies Support Allosteric Targeting of a Dual Specificity Phosphatase,” ChemBioChem 15, no. 10 (2014): 1436–1445.

[7] S. Mainardi, A. Mulero-Sánchez, A. Prahallad, et al., “SHP2 Is Required for Growth of KRAS-Mutant Non-Small-Cell Lung Cancer In Vivo,” Nature Medicine 24, no. 7 (2018): 961–967.

[8] P. Dutta and W. X. Li, “Role of the JAK-STAT Signalling Pathway in Cancer,” in Encyclopedia of Life Sciences (eLS) (Wiley, 2013), https://doi.org/10.1002/9780470015902.a002578.

[9] L. I. Pao, K. Badour, K. A. Siminovitch, and B. G. Neel, “Nonreceptor Protein-Tyrosine Phosphatases in Immune Cell Signaling,” Annual Review of Immunology 25, no. 1 (2007): 473–523.

[10] W. Zhang, Q. Huang, W. Xiao, et al., “Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis,” Frontiers in Immunology 11 (2020): 18.

[11] M. Dance, A. Montagner, J.-P. Salles, A. Yart, and P. Raynal, “The Molecular Functions of Shp2 in the Ras/Mitogen-Activated Protein Kinase (ERK1/2) Pathway,” Cellular Signalling 20, no. 3 (2008): 453–459.

[12] S. Sarmasti Emami, D. Zhang, and X. Yang, “Interaction of the Hippo Pathway and Phosphatases in Tumorigenesis,” Cancers 12, no. 9 (2020): 2438.

[13] L. R. Bollu, A. Mazumdar, M. I. Savage, and P. H. Brown, “Molecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer,” Clinical Cancer Research 23, no. 9 (2017): 2136–2142.

[14] A. Turdo, C. D'accardo, A. Glaviano, et al., “Targeting Phosphatases and Kinases: How to Checkmate Cancer,” Frontiers in Cell and Developmental Biology 9 (2021): 690306.

[15] F. Sacco, L. Perfetto, L. Castagnoli, and G. Cesareni, “The Human Phosphatase Interactome: An Intricate Family Portrait,” FEBS Letters 586, no. 17 (2012): 2732–2739.

[16] S. Mamoor, “ PTPN22 Expression Associates With Survival in Triple Negative Breast Cancer,” (preprint, 2021), https://doi.org/10.31219/osf.io/94mdp.

[17] E. Hoekstra, A. M. Das, M. Swets, et al., “Increased PTP1B Expression and Phosphatase Activity in Colorectal Cancer Results in a More Invasive Phenotype and Worse Patient Outcome,” Oncotarget 7, no. 16 (2016): 21922–21938.

[18] Y. Kang, A. S. Nagaraja, G. N. Armaiz-Pena, et al., “Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer,” Clinical Cancer Research 22, no. 7 (2016): 1713–1724.

[19] D. R. Myers, C. L. Abram, D. Wildes, et al., “Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity,” Frontiers in Immunology 11, no. 11 (2020): 576310.

[20] P. K. Goh, F. Wiede, M. N. Zeissig, et al., “PTPN2 Elicits Cell Autonomous and Non–Cell Autonomous Effects on Antitumor Immunity in Triple-Negative Breast Cancer,” Science Advances 8, no. 8 (2022): eabk3338.

[21] Z. Huang, M. Liu, D. Li, et al., “PTPN2 Regulates the Activation of KRAS and Plays a Critical Role in Proliferation and Survival of KRAS-Driven Cancer Cells,” Journal of Biological Chemistry 295, no. 52 (2020): 18343–18354.

[22] J. Sangodkar, A. Perl, R. Tohme, et al., “Activation of Tumor Suppressor Protein PP2A Inhibits KRAS-Driven Tumor Growth,” Journal of Clinical Investigation 127, no. 6 (2017): 2081–2090.

[23] S. Wang, W. Xie, D. Wang, et al., “Discovery of a Small Molecule Targeting SET-PP2A Interaction to Overcome BCR-ABLT315I Mutation of Chronic Myeloid Leukemia,” Oncotarget 6, no. 14 (2015): 12128–12140.

[24] J. Zhang, F. Zhang, and R. Niu, “Functions of Shp2 in Cancer,” Journal of Cellular and Molecular Medicine 19, no. 9 (2015): 2075–2083.

[25] P. S. Y. Chong, J. Zhou, J. S. L. Lim, et al., “IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma,” Cancer Research 79, no. 18 (2019): 4679–4688.

[26] D. G. Adams, R. L. Coffee , H. Zhang, S. Pelech, S. Strack, and B. E. Wadzinski, “Positive Regulation of Raf1-MEK1/2-ERK1/2 Signaling by Protein Serine/Threonine Phosphatase 2A Holoenzymes,” Journal of Biological Chemistry 280, no. 52 (2005): 42644–42654.

[27] X. Cai, L. Qu, J. Yang, et al., “Exosome–Transmitted microRNA-133b Inhibited Bladder Cancer Proliferation by Upregulating Dual-Specificity Protein Phosphatase 1,” Cancer Medicine 9, no. 16 (2020): 6009–6019.

[28] Y. Wu, W. Deng, E. C. McGinley, and D. J. Klinke, “Melanoma Exosomes Deliver a Complex Biological Payload That Upregulates PTPN 11 to Suppress T Lymphocyte Function,” Pigment Cell & Melanoma Research 30, no. 2 (2017): 203–218.

[29] X. Liu, J. Yu, and D. Chen, “Irradiated Tumor Cells-Derived Exosomes Modulate Macrophage Polarization by Targeting SHP-2 Mediated Metabolic Reprogramming,” International Journal of Radiation Oncology*Biology*Physics 117, no. 2 (2023): S167.

[30] H. Dong, C. Xie, Y. Jiang, et al., “Tumor-Derived Exosomal Protein Tyrosine Phosphatase Receptor Type O Polarizes Macrophage to Suppress Breast Tumor Cell Invasion and Migration,” Frontiers in Cell and Developmental Biology 9, no. 9 (2021): 703537.

[31] S.-W. Chen, S. Q. Zhu, X. Pei, et al., “Cancer Cell-Derived Exosomal circUSP7 Induces CD8+ T Cell Dysfunction and Anti-PD1 Resistance by Regulating the miR-934/SHP2 Axis in NSCLC,” Molecular Cancer 20, no. 1 (2021): 144.

[32] Y. Zhang, Y. Li, P. Liu, et al., “Phosphatase Shp2 Regulates Biogenesis of Small Extracellular Vesicles by Dephosphorylating Syntenin,” Journal of Extracellular Vesicles 10, no. 5 (2021): e12078.

[33] Z. Li, J. Xi, B. Li, et al., “SHP-2-induced M2 Polarization of Tumor Associated Macrophages via IL-4 Regulate Colorectal Cancer Progression,” Frontiers in Oncology 13, no. 13 (2023): 1027575.

[34] L. Dong, D. Han, X. Meng, M. Xu, C. Zheng, and Q. Xia, “Activating Mutation of SHP2 Establishes a Tumorigenic Phonotype Through Cell-Autonomous and Non-Cell-Autonomous Mechanisms,” Frontiers in Cell and Developmental Biology 9, no. 9 (2021): 630712.

[35] P. L. Chia, K. H. Ang, M. Thura, and Q. Zeng, “PRL3 as a Therapeutic Target for Novel Cancer Immunotherapy in Multiple Cancer Types,” Theranostics 13, no. 6 (2023): 1876–1891.

[36] L. R. Decotret, "Investigating Intrinsic and Extrinsic Factors That Regulate Cancer Cell Motility” (PhD Dissertation, University of British Columbia, 2022), https://open.library.ubc.ca/soa/cIRcle/collections/ubctheses/24/items/1.0413784.

[37] L. M. Scott, H. R. Lawrence, S. M. Sebti, N. J. Lawrence, and J. Wu, “Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery,” Current Pharmaceutical Design 16, no. 16 (2010): 1843–1862.

[38] Y. Song, S. Wang, M. Zhao, X. Yang, and B. Yu, “Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy,” Journal of Medicinal Chemistry 65, no. 4 (2022): 3066–3079.

[39] S. Bobone, L. Pannone, B. Biondi, et al., “Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting Its Protein–Protein Interactions,” Journal of Medicinal Chemistry 64, no. 21 (2021): 15973–15990.

[40] Y. Song, M. Zhao, H. Zhang, and B. Yu, “Double-Edged Roles of Protein Tyrosine Phosphatase SHP2 in Cancer and Its Inhibitors in Clinical Trials,” Pharmacology & Therapeutics 230, no. 230 (2022): 107966.

[41] M. Wei, K. V. Korotkov, and J. S. Blackburn, “Targeting Phosphatases of Regenerating Liver (PRLs) in Cancer,” Pharmacology & Therapeutics 190, no. 190 (2018): 128–138.

[42] B. Marsh-Armstrong, J. M. Fajnzylber, S. Korntner, B. A. Plaman, and A. C. Bishop, “The Allosteric Site on SHP2's Protein Tyrosine Phosphatase Domain Is Targetable With Druglike Small Molecules,” ACS Omega 3, no. 11 (2018): 15763–15770.

[43] A. Tojjari, A. Saeed, A. Sadeghipour, R. Kurzrock, and L. Cavalcante, “Overcoming Immune Checkpoint Therapy Resistance With SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches,” Cancers 15, no. 22 (2023): 5384.

[44] A. M. Smith, M. D. Dun, E. M. Lee, et al., “Activation of Protein Phosphatase 2A in FLT3+ Acute Myeloid Leukemia Cells Enhances the Cytotoxicity of FLT3 Tyrosine Kinase Inhibitors,” Oncotarget 7, no. 30 (2016): 47465–47478.

[45] A. Agarwal, R. J. MacKenzie, R. Pippa, et al., “Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia,” Clinical Cancer Research 20, no. 8 (2014): 2092–2103.

[46] Y.-N. P. Chen, M. J. LaMarche, H. M. Chan, et al., “Allosteric Inhibition of SHP2 Phosphatase Inhibits Cancers Driven by Receptor Tyrosine Kinases,” Nature 535, no. 7610 (2016): 148–152.

[47] N. M. Sodir, G. Pathria, J. I. Adamkewicz, et al., “SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment,” Cancer Discovery 13, no. 11 (2023): 2339–2355.

[48] Y. Ren, Z. Chen, L. Chen, et al., “Critical Role of Shp2 in Tumor Growth Involving Regulation of C-Myc,” Genes & Cancer 1, no. 10 (2010): 994–1007.

[49] L. M Scott, H. R Lawrence, S. M Sebti, N. J Lawrence, and J. Wu, “Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery,” Current Pharmaceutical Design 16, no. 16 (2010): 1843–1862.

[50] D. L. Brautigan and S. Shenolikar, “Protein Serine/Threonine Phosphatases: Keys to Unlocking Regulators and Substrates,” Annual Review of Biochemistry 87, no. 1 (2018): 921–964.

[51] D. P. Labbé, S. Hardy, and M. L. Tremblay, “Protein Tyrosine Phosphatases in Cancer: Friends and Foes!,” Progress in Molecular Biology and Translational Science 106 (2012): 253–306.

[52] N. K. Tonks, “Protein Tyrosine Phosphatases: From Genes, to Function, to Disease,” Nature Reviews Molecular Cell Biology 7, no. 11 (2006): 833–846.

[53] A. Alonso and R. Pulido, “The Extended Human PTP ome: A Growing Tyrosine Phosphatase Family,” FEBS Journal 283, no. 8 (2016): 1404–1429.

[54] W. J. A. J. Hendriks, A. Elson, S. Harroch, R. Pulido, A. Stoker, and J. den Hertog, “Protein Tyrosine Phosphatases in Health and Disease,” FEBS Journal 280, no. 2 (2013): 708–730.

[55] K. I. Patterson, T. Brummer, P. M. O'brien, and R. J. Daly, “Dual-Specificity Phosphatases: Critical Regulators With Diverse Cellular Targets,” Biochemical Journal 418, no. 3 (2009): 475–489.

[56] Z. Ye, A. Q. O. Al-Aidaroos, J. E. Park, et al., “PRL-3 Activates mTORC1 in Cancer Progression,” Scientific Reports 5, no. 1 (2015): 17046.

[57] J. C. Liu, L. Granieri, M. Shrestha, et al., “Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer,” Cell Reports 23, no. 1 (2018): 112–126.

[58] Y. Yu, M. Dai, L. Huang, et al., “PTEN Phosphatase Inhibits Metastasis by Negatively Regulating the Entpd5/Igf1r Pathway Through ATF6,” Iscience 26, no. 2 (2023): 106070.

[59] X. Hu, C. Garcia, L. Fazli, et al., “Inhibition of Pten Deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling Axis,” Scientific Reports 5, no. 1 (2015): 15182.

[60] P.-P. Gao, X. W. Qi, N. Sun, et al., “The Emerging Roles of Dual-Specificity Phosphatases and Their Specific Characteristics in Human Cancer,” Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1876, no. 1 (2021): 188562.

[61] W. J. Ho, S. Croessmann, J. Lin, et al., “Systemic Inhibition of PTPN22 Augments Anticancer Immunity,” Journal of Clinical Investigation 131, no. 17 (2021): e146950.

[62] B. Hu, S. Hao, Y. Miao, et al., “Inhibiting PP2A Upregulates B7-H3 Expression and Potentially Increases the Sensitivity of Malignant Meningiomas to Immunotherapy by Proteomics,” Pathology Oncology Research: POR 28, no. 28 (2022): 1610572.

[63] M. Di Crosta, A. Arena, R. Benedetti, M. S. Gilardini Montani, and M. Cirone, “5-Aza Upregulates SOCS3 and PTPN6/SHP1, Inhibiting STAT3 and Potentiating the Effects of AG490 Against Primary Effusion Lymphoma Cells,” Current Issues in Molecular Biology 46, no. 3 (2024): 2468–2479.

[64] P. P. Ruvolo, “Role of Protein Phosphatases in the Cancer Microenvironment,” Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1866, no. 1 (2019): 144–152.

[65] F. Liang, J. Liang, W. Q. Wang, J. P. Sun, E. Udho, and Z. Y. Zhang, “PRL3 Promotes Cell Invasion and Proliferation by Down-Regulation of Csk Leading to Src Activation,” Journal of Biological Chemistry 282, no. 8 (2007): 5413–5419.

[66] J. Zhou, H. Guo, Y. Zhang, H. Liu, and Q. Dou, “The Role of PTP1B (PTPN1) in the Prognosis of Solid Tumors: A Meta-Analysis,” Medicine 101, no. 40 (2022): e30826.

[67] J. Shen, Y. Zhang, H. Yu, et al., “Role of DUSP1/MKP1 in Tumorigenesis, Tumor Progression and Therapy,” Cancer Medicine 5, no. 8 (2016): 2061–2068.

[68] J. Gu, T. Han, R. H. Ma, et al., “SHP2 Promotes Laryngeal Cancer Growth Through the Ras/Raf/Mek/Erk Pathway and Serves as a Prognostic Indicator for Laryngeal Cancer,” International Journal of Oncology 44, no. 2 (2013): 481–490.

[69] B. Cheatham, C. R. Kahn, and B. Cheatham, “Insulin Action and the Insulin Signaling Network,” Endocrine Reviews 16, no. 2 (1995): 117–142.

[70] X. Tang, C. Qi, H. Zhou, and Y. Liu, “Critical Roles of PTPN Family Members Regulated by Non-Coding RNAs in Tumorigenesis and Immunotherapy,” Frontiers in Oncology 12 (2022): 972906.

[71] V. Sivaganesh, V. Sivaganesh, C. Scanlon, et al., “Protein Tyrosine Phosphatases: Mechanisms in Cancer,” International Journal of Molecular Sciences 22, no. 23 (2021): 12865.

[72] C. J. Caunt and S. M. Keyse, “Dual-Specificity MAP Kinase Phosphatases (MKPs) Shaping the Outcome of MAP Kinase Signalling,” FEBS Journal 280, no. 2 (2013): 489–504.

[73] C. T. Kaltenmeier, L. L. Vollmer, L. A. Vernetti, et al., “A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity,” Journal of Pharmacology and Experimental Therapeutics 361, no. 1 (2017): 39–50.

[74] M. Kesarwani, Z. Kincaid, A. Gomaa, et al., “Targeting c-FOS and DUSP1 Abrogates Intrinsic Resistance to Tyrosine-Kinase Inhibitor Therapy in BCR-ABL-Induced Leukemia,” Nature Medicine 23, no. 4 (2017): 472–482.

[75] L. Duciel, L. C. Monraz Gomez, M. Kondratova, I. Kuperstein, and S. Saule, “The Phosphatase PRL-3 Is Involved in Key Steps of Cancer Metastasis,” Journal of Molecular Biology 431, no. 17 (2019): 3056–3067.

[76] H. Wang, S. Y. Quah, J. M. Dong, E. Manser, J. P. Tang, and Q. Zeng, “PRL-3 Down-Regulates Pten Expression and Signals Through PI3K to Promote Epithelial-Mesenchymal Transition,” Cancer Research 67, no. 7 (2007): 2922–2926.

[77] Q. Zeng, W. Hong, and Y. H. Tan, “Mouse PRL-2 and PRL-3, Two Potentially Prenylated Protein Tyrosine Phosphatases Homologous to PRL-1,” Biochemical and Biophysical Research Communications 244, no. 2 (1998): 421–427.

[78] D. G. Molleví, A. Aytes, M. Berdiel, et al., “PRL-3 Overexpression in Epithelial Cells Is Induced by Surrounding Stromal Fibroblasts,” Molecular cancer 8 (2009): 46.

[79] D. J. Kim, M. L. Tremblay, and J. DiGiovanni, “Protein Tyrosine Phosphatases, TC-PTP, SHP1, and SHP2, Cooperate in Rapid Dephosphorylation of Stat3 in Keratinocytes Following UVB Irradiation,” PLoS One 5, no. 4 (2010): e10290.

[80] A. Zehender, J. Huang, A. H. Györfi, et al., “The Tyrosine Phosphatase SHP2 Controls TGFβ-induced STAT3 Signaling to Regulate Fibroblast Activation and Fibrosis,” Nature Communications 9, no. 1 (2018): 3259.

[81] E. A. Bard-Chapeau, S. Li, J. Ding, et al., “Ptpn11/Shp2 Acts as a Tumor Suppressor in Hepatocellular Carcinogenesis,” Cancer Cell 19, no. 5 (2011): 629–639.

[82] H. Fowle, Z. Zhao, and X. Graña, “PP2A Holoenzymes, Substrate Specificity Driving Cellular Functions and Deregulation in Cancer,” Advances in Cancer Research 144 (2019): 55–93.

[83] D. L. Brautigan, C. Farrington, and G. Narla, “Targeting Protein Phosphatase PP2A for Cancer Therapy: Development of Allosteric Pharmaceutical Agents,” Clinical Science 135, no. 13 (2021): 1545–1556.

[84] K. G. Roberts, A. M. Smith, F. McDougall, et al., “Essential Requirement for PP2A Inhibition by the Oncogenic Receptor C-Kit Suggests PP2A Reactivation as a Strategy to Treat C-Kit+ Cancers,” Cancer Research 70, no. 13 (2010): 5438–5447.

[85] Z. Liu, J. Wang, F. Dai, D. Zhang, and W. Li, “DUSP1 Mediates BCG Induced Apoptosis and Inflammatory Response in THP-1 Cells via MAPKs/NF-κB Signaling Pathway,” Scientific Reports 13, no. 1 (2023): 2606.

[86] N. Fu, R. Xi, X. Shi, et al., “Hexachlorophene, a Selective SHP2 Inhibitor, Suppresses Proliferation and Metastasis of KRAS-Mutant NSCLC Cells by Inhibiting RAS/MEK/ERK and PI3K/AKT Signaling Pathways,” Toxicology and Applied Pharmacology 441, no. 441 (2022): 115988.

[87] Y. Tang, G. Fang, F. Guo, et al., “Selective Inhibition of STRN3-containing PP2A Phosphatase Restores Hippo Tumor-Suppressor Activity in Gastric Cancer,” Cancer Cell 38, no. 1 (2020): 115–128.e9.

[88] D. Xu and C. K. Qu, “Protein Tyrosine Phosphatases in the JAK/STAT Pathway,” Frontiers in Bioscience 13 (2008): 4925.

[89] N. R. D. Paling and M. J. Welham, “Tyrosine Phosphatase SHP-1 Acts at Different Stages of Development to Regulate Hematopoiesis,” Blood 105, no. 11 (2005): 4290–4297.

[90] F. Hao, C. Wang, C. Sholy, M. Cao, and X. Kang, “Strategy for Leukemia Treatment Targeting SHP-1, 2 and SHIP,” Frontiers in Cell and Developmental Biology 9, no. 9 (2021): 730400.

[91] A. Varone, D. Spano, and D. Corda, “Shp1 in Solid Cancers and Their Therapy,” Frontiers in Oncology 10, no. 10 (2020): 935.

[92] R. Cubas, Z. Khan, Q. Gong, et al., “Autoimmunity Linked Protein Phosphatase PTPN22 as a Target for Cancer Immunotherapy,” Journal for Immunotherapy of Cancer 8, no. 2 (2020): e001439.

[93] H. Chen, G. M. Cresswell, S. Libring, et al., “Tumor Cell–Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer,” Cancer Research Communications 2, no. 10 (2022): 1104–1118.

[94] L. Lessard, D. P. Labbé, G. Deblois, et al., “PTP1B Is an Androgen Receptor–Regulated Phosphatase That Promotes the Progression of Prostate Cancer,” Cancer Research 72, no. 6 (2012): 1529–1537.

[95] Q.-N. Wu, Y. F. Liao, Y. X. Lu, et al., “Pharmacological Inhibition of DUSP6 Suppresses Gastric Cancer Growth and Metastasis and Overcomes Cisplatin Resistance,” Cancer Letters 412, no. 412 (2018): 243–255.

[96] L. Martin, R. Patel, J. Zhang, et al., “Abstract 2671: ERAS-601, a Potent Allosteric Inhibitor of SHP2, Demonstrates Anti-Tumor Activity in RAS/MAPK-Driven Tumor Models,” supplement, Cancer Research 82, no. S12 (2022): 2671.

[97] C. Yan, J. Yang, N. Saleh, et al., “Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer,” International Journal of Molecular Sciences 22, no. 10 (2021): 5207.

[98] Z. Pan, J. Bao, L. Zhang, and S. Wei, “UBE2D3 Activates SHP-2 Ubiquitination to Promote Glycolysis and Proliferation of Glioma via Regulating STAT3 Signaling Pathway,” Frontiers in Oncology 11 (2021): 674286.

[99] U. Lorenz, “SHP-1 and SHP-2 in T Cells: Two Phosphatases Functioning at Many Levels,” Immunological Reviews 228, no. 1 (2009): 342–359.

[100] Y. Zhao and L. Jiang, “Targeting SHP1 and SHP2 to Suppress Tumors and Enhance Immunosurveillance,” Trends in Cell Biology, ahead of print, November 21, 2024, https://doi.org/10.1016/j.tcb.2024.10.008.

[101] H. Nakagami, T. X. Cui, M. Iwai, et al., “Tumor Necrosis Factor-α Inhibits Growth Factor-Mediated Cell Proliferation Through SHP-1 Activation in Endothelial Cells,” Arteriosclerosis, Thrombosis, and Vascular Biology 22, no. 2 (2002): 238–242.

[102] E. Tibaldi, F. Zonta, L. Bordin, et al., “The Tyrosine Phosphatase SHP-1 Inhibits Proliferation of Activated Hepatic Stellate Cells by Impairing PDGF Receptor Signaling,” Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1843, no. 2 (2014): 288–298.

[103] M. Garg and M. Wahid, “Regulation of Peripheral and Central Immunity: Understanding the Role of Src Homology 2 Domain-Containing Tyrosine Phosphatases, SHP-1 & SHP-2,” Immunobiology 225, no. 1 (2020): 151847.

[104] J. P. Snook, A. J. Soedel, H. A. Ekiz, R. M. O'Connell, and M. A. Williams, “Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade,” Cancer Immunology Research 8, no. 4 (2020): 506–517.

[105] M. T. Stephan, S. B. Stephan, P. Bak, J. Chen, and D. J. Irvine, “Synapse-Directed Delivery of Immunomodulators Using T-Cell-Conjugated Nanoparticles,” Biomaterials 33, no. 23 (2012): 5776–5787.

[106] P. Minoo, M. M. Zadeh, R. Rottapel, J.-J. Lebrun, and S. Ali, “A Novel SHP-1/Grb2–dependent Mechanism of Negative Regulation of Cytokine-Receptor Signaling: Contribution of SHP-1 C-Terminal Tyrosines in Cytokine Signaling,” Blood 103, no. 4 (2004): 1398–1407.

[107] J. Zhou, Z. Tang, S. Gao, C. Li, Y. Feng, and X. Zhou, “Tumor-Associated Macrophages: Recent Insights and Therapies,” Frontiers in Oncology 10 (2020): 188.

[108] L. Ghimire and H. R. Luo, “Balancing Immune Response: SHP1 Controls Neutrophil Activation in Inflamed Lungs,” Journal of Clinical Investigation 134, no. 24 (2024): e187056.

[109] Y. Liu, J. Zhang, Z. Du, et al., “Comprehensive Analysis of PTPN Family Expression and Prognosis in Acute Myeloid Leukemia,” Frontiers in Genetics 13 (2023): 1087938.

[110] S. Lim, K. W. Lee, J. Y. Kim, and K. D. Kim, “Consideration of SHP-1 as a Molecular Target for Tumor Therapy,” International Journal of Molecular Sciences 25, no. 1 (2023): 331.

[111] X. Piao, R. Paulson, P. van der Geer, T. Pawson, and A. Bernstein, “Oncogenic Mutation in the Kit Receptor Tyrosine Kinase Alters Substrate Specificity and Induces Degradation of the Protein Tyrosine Phosphatase Shp-1,” Proceedings of the National Academy of Sciences 93, no. 25 (1996): 14665–14669.

[112] A. Beghini, C. B. Ripamonti, P. Peterlongo, et al., “RNA Hyperediting and Alternative Splicing of Hematopoietic Cell Phosphatase (PTPN6) Gene in Acute Myeloid Leukemia,” Human Molecular Genetics 9, no. 15 (2000): 2297–2304.

[113] L.-C. Fan, H. W. Teng, C. W. Shiau, et al., “Regorafenib (Stivarga) Pharmacologically Targets Epithelial-Mesenchymal Transition in Colorectal Cancer,” Oncotarget 7, no. 39 (2016): 64136–64147.

[114] T. Iype, M. Sankarshanan, I. S. Mauldin, D. W. Mullins, and U. Lorenz, “The Protein Tyrosine Phosphatase SHP-1 Modulates the Suppressive Activity of Regulatory T Cells,” Journal of Immunology 185, no. 10 (2010): 6115–6127.

[115] N. Monu and A. B. Frey, “Suppression of Proximal T Cell Receptor Signaling and Lytic Function in CD8+ Tumor-Infiltrating T Cells,” Cancer Research 67, no. 23 (2007): 11447–11454.

[116] E. Baghbani, V. Khaze, S. Sadreddini, et al., “PTPN22 Silencing in Human Acute T-Cell Leukemia Cell Line (Jurkat Cell) and Its Effect on the Expression of miR-181a and miR-181b,” Advanced Pharmaceutical Bulletin 8, no. 2 (2018): 277–282.

[117] R. J. Brownlie, C. Garcia, M. Ravasz, D. Zehn, R. J. Salmond, and R. Zamoyska, “Resistance to TGFβ Suppression and Improved Anti-Tumor Responses in CD8+ T Cells Lacking PTPN22,” Nature Communications 8, no. 1 (2017): 1343.

[118] R. J. Brownlie, R. Zamoyska, and R. J. Salmond, “Regulation of Autoimmune and Anti-Tumour T-Cell Responses by PTPN 22,” Immunology 154, no. 3 (2018): 377–382.

[119] R. J. Brownlie, D. Wright, R. Zamoyska, and R. J. Salmond, “Deletion of PTPN22 Improves Effector and Memory CD8+ T Cell Responses to Tumors,” JCI Insight 4, no. 16 (2019): e127847.

[120] X. Yu, J. P. Sun, Y. He, et al., “Structure, Inhibitor, and Regulatory Mechanism of Lyp, a Lymphoid-Specific Tyrosine Phosphatase Implicated in Autoimmune Diseases,” Proceedings of the National Academy of Sciences 104, no. 50 (2007): 19767–19772.

[121] B. A. Jassim, J. Lin, and Z.-Y. Zhang, “PTPN22: Structure, Function, and Developments in Inhibitor Discovery With Applications for Immunotherapy,” Expert Opinion on Drug Discovery 17, no. 8 (2022): 825–837.

[122] S. Dolaner, H. Kaur, E. Brodsky, J. Panov, and M. Mazumder, “Identification of LncRNAs as Therapeutic Targets in Chronic Lymphocytic Leukemia,” Columbia Undergraduate Science Journal 15, no. 15 (2021): 16–29.

[123] X. Liang, H. Zhao, J. Du, et al., “Discovery of benzofuran-2-carboxylic Acid Derivatives as Lymphoid Tyrosine Phosphatase (LYP) Inhibitors for Cancer Immunotherapy,” European Journal of Medicinal Chemistry 258, no. 258 (2023): 115599.

[124] J. M. Balko, L. J. Schwarz, N. E. Bhola, et al., “Activation of MAPK Pathways Due to DUSP4 Loss Promotes Cancer Stem Cell-Like Phenotypes in Basal-Like Breast Cancer,” Cancer Research 73, no. 20 (2013): 6346–6358.

[125] L. Palacios, R. J. Dickinson, A. Sacristán-Reviriego, et al., “Distinct Docking Mechanisms Mediate Interactions Between the Msg5 Phosphatase and Mating or Cell Integrity Mitogen-Activated Protein Kinases (MAPKs) in Saccharomyces cerevisiae,” Journal of Biological Chemistry 286, no. 49 (2011): 42037–42050.

[126] L. N. Chan, M. A. Murakami, M. E. Robinson, et al., “Signalling Input From Divergent Pathways Subverts B Cell Transformation,” Nature 583, no. 7818 (2020): 845–851.

[127] G. Molina, A. Vogt, A. Bakan, et al., “Zebrafish Chemical Screening Reveals an Inhibitor of Dusp6 That Expands Cardiac Cell Lineages,” Nature Chemical Biology 5, no. 9 (2009): 680–687.

[128] S. Vicent, M. Garayoa, M. López-Picazo, et al., “Mitogen-Activated Protein Kinase phosphatase-1 Is Overexpressed in Non-Small Cell Lung Cancer and Is an Independent Predictor of Outcome in Patients,” Clinical Cancer Research 10, no. 11 (2004): 3639–3649.

[129] H.-Y. Chen, S. L. Yu, C. H. Chen, et al., “A Five-Gene Signature and Clinical Outcome in Non–Small-Cell Lung Cancer,” New England Journal of Medicine 356, no. 1 (2007): 11–20.

[130] V. Moncho-Amor, I. Ibañez de Cáceres, E. Bandres, et al., “DUSP1/MKP1 Promotes Angiogenesis, Invasion and Metastasis in Non-Small-Cell Lung Cancer,” Oncogene 30, no. 6 (2011): 668–678.

[131] Z. R. Li, Z. Wang, B. H. Zhu, et al., “Association of Tyrosine PRL-3 Phosphatase Protein Expression With Peritoneal Metastasis of Gastric Carcinoma and Prognosis,” Surgery Today 37, no. 37 (2007): 646–651.

[132] S. Shojaee, R. Caeser, M. Buchner, et al., “Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia,” Cancer Cell 28, no. 1 (2015): 114–128.

[133] A. Q. O. Al-Aidaroos, H. F. Yuen, K. Guo, et al., “Metastasis-Associated PRL-3 Induces EGFR Activation and Addiction in Cancer Cells,” Journal of Clinical Investigation 123, no. 8 (2013): 3459–3471.

[134] M. Thura, A. Q. Al-Aidaroos, A. Gupta, et al., “PRL3-zumab as an Immunotherapy to Inhibit Tumors Expressing PRL3 Oncoprotein,” Nature Communications 10, no. 1 (2019): 2484.

[135] Q. Zeng, J. M. Dong, K. Guo, et al., “PRL-3 and PRL-1 Promote Cell Migration, Invasion, and Metastasis,” Cancer Research 63, no. 11 (2003): 2716–2722.

[136] Q. Zhou, Q. Zhou, Q. Liu, et al., “PRL-3 Facilitates Hepatocellular Carcinoma Progression by Co-Amplifying With and Activating FAK,” Theranostics 10, no. 22 (2020): 10345–10359.

[137] A. Ooki, K. Yamashita, S. Kikuchi, et al., “Therapeutic Potential of PRL-3 Targeting and Clinical Significance of PRL-3 Genomic Amplification in Gastric Cancer,” BMC Cancer 11 (2011): 122.

[138] D. R. Edwards, K. Moroz, H. Zhang, D. Mulholland, A. B. Abdel-Mageed, and D. Mondal, “PRL‑3 Increases the Aggressive Phenotype of Prostate Cancer Cells In Vitro and Its Expression Correlates With High-Grade Prostate Tumors in Patients,” International Journal of Oncology 52, no. 2 (2018): 402–412.

[139] E. Kostantin, S. Hardy, W. C. Valinsky, et al., “Inhibition of PRL-2· CNNM3 Protein Complex Formation Decreases Breast Cancer Proliferation and Tumor Growth,” Journal of Biological Chemistry 291, no. 20 (2016): 10716–10725.

[140] Y. Funato, D. Yamazaki, S. Mizukami, L. Du, K. Kikuchi, and H. Miki, “Membrane Protein CNNM4–dependent Mg2+ Efflux Suppresses Tumor Progression,” Journal of Clinical Investigation 124, no. 12 (2014): 5398–5410.

[141] Y. Liu, J. Zhou, J. Chen, et al., “PRL-3 Promotes Epithelial Mesenchymal Transition by Regulating Cadherin Directly,” Cancer Biology & Therapy 8, no. 14 (2009): 1352–1359.

[142] H. Xu, W. Lai, Y. Zhang, et al., “Tumor-Associated Macrophage-Derived IL-6 and IL-8 Enhance Invasive Activity of Lovo Cells Induced by PRL-3 in a KCNN4 Channel-Dependent Manner,” BMC Cancer 14 (2014): 330.

[143] Q. Lan, W. Lai, Y. Zeng, et al., “CCL26 Participates in the PRL-3-induced Promotion of Colorectal Cancer Invasion by Stimulating Tumor-Associated Macrophage Infiltration,” Molecular Cancer Therapeutics 17, no. 1 (2018): 276–289.

[144] J. M. Salamoun, K. E. McQueeney, K. Patil, et al., “Photooxygenation of an Amino-Thienopyridone Yields a More Potent PTP4A3 Inhibitor,” Organic & Biomolecular Chemistry 14, no. 27 (2016): 6398–6402.

[145] J. S. Lazo, I. K. Blanco, N. R. Tasker, et al., “Next-Generation Cell-Active Inhibitors of the Undrugged Oncogenic PTP4A3 Phosphatase,” Journal of Pharmacology and Experimental Therapeutics 371, no. 3 (2019): 652–662.

[146] K. E. McQueeney, J. M. Salamoun, J. C. Burnett, et al., “Targeting Ovarian Cancer and Endothelium With an Allosteric PTP4A3 Phosphatase Inhibitor,” Oncotarget 9, no. 9 (2018): 8223–8240.

[147] O. Villamar-Cruz, M. A. Loza-Mejía, L. E. Arias-Romero, and I. Camacho-Arroyo, “Recent Advances in PTP1B Signaling in Metabolism and Cancer,” Bioscience Reports 41, no. 11 (2021): BSR20211994.

[148] F. Wiede, K. H. Lu, X. Du, et al., “PTP1B Is an Intracellular Checkpoint That Limits T-Cell and CAR T-Cell Antitumor Immunity,” Cancer Discovery 12, no. 3 (2022): 752–773.

[149] A. Elson, “Stepping out of the Shadows: Oncogenic and Tumor-Promoting Protein Tyrosine Phosphatases,” International Journal of Biochemistry & Cell Biology 96, no. 96 (2018): 135–147.

[150] Q. Xu, N. Wu, X. Li, et al., “Inhibition of PTP1B Blocks Pancreatic Cancer Progression by Targeting the PKM2/AMPK/mTOC1 Pathway,” Cell Death & Disease 10, no. 12 (2019): 874.

[151] K. Zahra, T. Dey, Ashish , S. P. Mishra, U. Pandey, “Pyruvate Kinase M2 and Cancer: The Role of PKM2 in Promoting Tumorigenesis,” Frontiers in Oncology 10 (2020): 159.

[152] E. Karaca Atabay, C. Mecca, Q. Wang, et al., “Tyrosine Phosphatases Regulate Resistance to ALK Inhibitors in ALK+ Anaplastic Large Cell Lymphoma,” Blood 139, no. 5 (2022): 717–731.

[153] P. André, C. Denis, C. Soulas, et al., “Anti-NKG2A mAb Is a Checkpoint Inhibitor That Promotes Anti-Tumor Immunity by Unleashing Both T and NK Cells,” Cell 175, no. 7 (2018): 1731–1743.e13.

[154] L. Ou, A. Zhang, Y. Cheng, and Y. Chen, “The cGAS-STING Pathway: A Promising Immunotherapy Target,” Frontiers in Immunology 12 (2021): 795048.

[155] N. E. Read and H. M. Wilson, “Recent Developments in the Role of Protein Tyrosine Phosphatase 1B (PTP1B) as a Regulator of Immune Cell Signalling in Health and Disease,” International Journal of Molecular Sciences 25, no. 13 (2024): 7207.

[156] T. Woodford-Thomas, J. Rhodes, and J. Dixon, “Expression of a Protein Tyrosine Phosphatase in Normal and v-src-Transformed Mouse 3T3 Fibroblasts,” Journal of Cell Biology 117, no. 2 (1992): 401–414.

[157] K. R. LaMontagne, , G. Hannon, and N. K. Tonks, “Protein Tyrosine Phosphatase PTP1B Suppresses p210 bcr-abl-Induced Transformation of rat-1 Fibroblasts and Promotes Differentiation of K562 Cells,” Proceedings of the National Academy of Sciences 95, no. 24 (1998): 14094–14099.

[158] L. Lessard, M. Stuible, and M. L. Tremblay, “The Two Faces of PTP1B in Cancer,” Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1804, no. 3 (2010): 613–619.

[159] Á. González-Rodriguez, Ó. Escribano, J. Alba, C. M. Rondinone, M. Benito, and Á. M. Valverde, “Levels of Protein Tyrosine Phosphatase 1B Determine Susceptibility to Apoptosis in Serum-Deprived Hepatocytes,” Journal of Cellular Physiology 212, no. 1 (2007): 76–88.

[160] C. L. Cortesio, K. T. Chan, B. J. Perrin, et al., “Calpain 2 and PTP1B Function in a Novel Pathway With Src to Regulate Invadopodia Dynamics and Breast Cancer Cell Invasion,” Journal of Cell Biology 180, no. 5 (2008): 957–971.

[161] C. Blanquart, S.-E. Karouri, and T. Issad, “Implication of Protein Tyrosine Phosphatase 1B in MCF-7 Cell Proliferation and Resistance to 4-OH Tamoxifen,” Biochemical and Biophysical Research Communications 387, no. 4 (2009): 748–753.

[162] J. Balsamo, C. Arregui, T. Leung, and J. Lilien, “The Nonreceptor Protein Tyrosine Phosphatase PTP1B Binds to the Cytoplasmic Domain of N-Cadherin and Regulates the Cadherin–Actin Linkage,” Journal of Cell Biology 143, no. 2 (1998): 523–532.

[163] N. Dubé, A. Bourdeau, K. M. Heinonen, A. Cheng, A. Lee Loy, and M. L. Tremblay, “Genetic Ablation of Protein Tyrosine Phosphatase 1B Accelerates Lymphomagenesis of p53-null Mice Through the Regulation of B-Cell Development,” Cancer Research 65, no. 21 (2005): 10088–10095.

[164] S. Liang, E. Tran, X. Du, et al., “A Small Molecule Inhibitor of PTP1B and PTPN2 Enhances T Cell Anti-Tumor Immunity,” Nature Communications 14, no. 1 (2023): 4524.

[165] M. Muppirala, V. Gupta, and G. Swarup, “Emerging Role of Tyrosine Phosphatase, TCPTP, in the Organelles of the Early Secretory Pathway,” Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1833, no. 5 (2013): 1125–1132.

[166] V. Vinette, I. Aubry, H. Insull, N. Uetani, S. Hardy, and M. L. Tremblay, “Protein Tyrosine Phosphatome Metabolic Screen Identifies TC-PTP as a Positive Regulator of Cancer Cell Bioenergetics and Mitochondrial Dynamics,” FASEB Journal 35, no. 7 (2021): e21708.

[167] J. Chen, X. Zhao, Y. Yuan, and J.-J. Jing, “The Expression Patterns and the Diagnostic/Prognostic Roles of PTPN Family Members in Digestive Tract Cancers,” Cancer Cell International 20 (2020): 238.

[168] P. Wang, H. Cai, C. Zhang, et al., “Molecular and Clinical Characterization of PTPN2 Expression From RNA-Seq Data of 996 Brain Gliomas,” Journal of Neuroinflammation 15 (2018): 145.

[169] L. Wu, F. Wang, J. Xu, and Z. Chen, “PTPN2 Induced by Inflammatory Response and Oxidative Stress Contributed to Glioma Progression,” Journal of Cellular Biochemistry 120, no. 11 (2019): 19044–19051.

[170] B. J. Shields, F. Wiede, E. N. Gurzov, et al., “TCPTP Regulates SFK and STAT3 Signaling and Is Lost in Triple-Negative Breast Cancers,” Molecular and Cellular Biology 33, no. 3 (2013): 557–570.

[171] K. A. Pike and M. L. Tremblay, “TC-PTP and PTP1B: Regulating JAK–STAT Signaling, Controlling Lymphoid Malignancies,” Cytokine 82 (2016): 52–57.

[172] M. W. LaFleur, T. H. Nguyen, M. A. Coxe, et al., “PTPN2 Regulates the Generation of Exhausted CD8+ T Cell Subpopulations and Restrains Tumor Immunity,” Nature Immunology 20, no. 10 (2019): 1335–1347.

[173] C. K. Baumgartner, H. Ebrahimi-Nik, A. Iracheta-Vellve, et al., “The PTPN2/PTPN1 Inhibitor ABBV-CLS-484 Unleashes Potent Anti-Tumour Immunity,” Nature 622, no. 7984 (2023): 850–862.

[174] F. Xu, J. Li, M. Ai, et al., “Penfluridol Inhibits Melanoma Growth and Metastasis Through Enhancing Von Hippel‒Lindau Tumor Suppressor-Mediated Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) Degradation,” MedComm 5, no. 10 (2024): e758.

[175] A. P. Williams, E. F. Garner, A. M. Waters, et al., “Investigation of PP2A and Its Endogenous Inhibitors in Neuroblastoma Cell Survival and Tumor Growth,” Translational Oncology 12, no. 1 (2019): 84–95.

[176] Y. T. Yen, M. Chien, P. Y. Wu, et al., “Protein Phosphatase 2A Inactivation Induces Microsatellite Instability, Neoantigen Production and Immune Response,” Nature Communications 12, no. 1 (2021): 7297.

[177] M. A. Pagano, E. Tibaldi, P. Molino, et al., “Mitochondrial Apoptosis Is Induced by Alkoxy Phenyl-1-Propanone Derivatives Through PP2A-Mediated Dephosphorylation of Bad and Foxo3A in CLL,” Leukemia 33, no. 5 (2019): 1148–1160.

[178] R. Rincón, I. Cristóbal, S. Zazo, et al., “PP2A Inhibition Determines Poor Outcome and Doxorubicin Resistance in Early Breast Cancer and Its Activation Shows Promising Therapeutic Effects,” Oncotarget 6, no. 6 (2015): 4299–4314.

[179] A. Kwok, N. Raulf, and N. Habib, “Developing Small Activating RNA as a Therapeutic: Current Challenges and Promises,” Therapeutic Delivery 10, no. 3 (2019): 151–164.

[180] C. Vicente, E. Arriazu, E. Martínez-Balsalobre, et al., “A Novel FTY720 Analogue Targets SET-PP2A Interaction and Inhibits Growth of Acute Myeloid Leukemia Cells Without Inducing Cardiac Toxicity,” Cancer Letters 468, no. 468 (2020): 1–13.

[181] A. Gutierrez, L. Pan, R. W. J. Groen, et al., “Phenothiazines Induce PP2A-Mediated Apoptosis in T Cell Acute Lymphoblastic Leukemia,” Journal of Clinical Investigation 124, no. 2 (2014): 644–655.

[182] D. B. Kastrinsky, J. Sangodkar, N. Zaware, et al., “Reengineered Tricyclic Anti-Cancer Agents,” Bioorganic & Medicinal Chemistry 23, no. 19 (2015): 6528–6534.

[183] P. Neviani, J. G. Harb, J. J. Oaks, et al., “PP2A-Activating Drugs Selectively Eradicate TKI-Resistant Chronic Myeloid Leukemic Stem Cells,” Journal of Clinical Investigation 123, no. 10 (2013): 4144–4157.

[184] S. A. Saddoughi, S. Gencer, Y. K. Peterson, et al., “Sphingosine Analogue Drug FTY720 Targets I2PP2A/SET and Mediates Lung Tumour Suppression via Activation of PP2A-RIPK1-Dependent Necroptosis,” EMBO Molecular Medicine 5, no. 1 (2013): 105–121.

[185] M. Ciccone, G. A. Calin, and D. Perrotti, “From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies,” Frontiers in Oncology 5, no. 5 (2015): 21.

[186] M. Swingle, L. Ni, and R. E. Honkanen, “Small-Molecule Inhibitors of ser/thr Protein Phosphatases: Specificity, Use and Common Forms of Abuse,” Methods in Molecular Biology (Clifton, N.J.) 365 (2007): 23–38.

[187] P. Zhou, D. R. Shaffer, D. A. Alvarez Arias, et al., “In Vivo Discovery of Immunotherapy Targets in the Tumour Microenvironment,” Nature 506, no. 7486 (2014): 52–57.

[188] O. Kauko and J. Westermarck, “Non-Genomic Mechanisms of Protein Phosphatase 2A (PP2A) Regulation in Cancer,” International Journal of Biochemistry & Cell Biology 96, no. 96 (2018): 157–164.

[189] R. Eil, S. K. Vodnala, D. Clever, et al., “Ionic Immune Suppression Within the Tumour Microenvironment Limits T Cell Effector Function,” Nature 537, no. 7621 (2016): 539–543.

[190] W. S. Ho, H. Wang, D. Maggio, et al., “Pharmacologic Inhibition of Protein Phosphatase-2A Achieves Durable Immune-Mediated Antitumor Activity When Combined With PD-1 Blockade,” Nature Communications 9, no. 1 (2018): 2126.

[191] D. Maggio, W. S. Ho, R. Breese, et al., “Inhibition of Protein phosphatase-2A With LB-100 Enhances Antitumor Immunity Against Glioblastoma,” Journal of Neuro-Oncology 148, no. 148 (2020): 231–244.

[192] S. A. Apostolidis, N. Rodríguez-Rodríguez, A. Suárez-Fueyo, et al., “Phosphatase PP2A Is Requisite for the Function of Regulatory T Cells,” Nature Immunology 17, no. 5 (2016): 556–564.

[193] P. Goguet-Rubio, P. Amin, S. Awal, et al., “PP2A-B55 Holoenzyme Regulation and Cancer,” Biomolecules 10, no. 11 (2020): 1586.

[194] G. Chan, D. Kalaitzidis, and B. G. Neel, “The Tyrosine Phosphatase Shp2 (PTPN11) in Cancer,” Cancer and Metastasis Reviews 27, no. 27 (2008): 179–192.

[195] B. G. Neel, H. Gu, and L. Pao, “The ‘Shp'ing News: SH2 Domain-Containing Tyrosine Phosphatases in Cell Signaling,” Trends in Biochemical Sciences 28, no. 6 (2003): 284–293.

[196] B. Popescu, C. Stahlhut, T. C. Tarver, et al., “Allosteric SHP2 Inhibition Increases Apoptotic Dependency on BCL2 and Synergizes With Venetoclax in FLT3-and KIT-Mutant AML,” Cell Reports Medicine 4, no. 11 (2023): 101290.

[197] K. Yu, Y. Yin, D. Dan Ma, et al., “Shp2 Activation in Bone Marrow Microenvironment Mediates the Drug Resistance of B-Cell Acute Lymphoblastic Leukemia Through Enhancing the Role of VCAM-1/VLA-4,” International Immunopharmacology 80, no. 80 (2020): 106008.

[198] M.-J. Chen, Y.-C. Wang, D.-W. Wu, C.-Y. Chen, and H. Lee, “Association of Nuclear Localization of SHP2 and YAP1 With Unfavorable Prognosis in Non-Small Cell Lung Cancer,” Pathology-Research and Practice 215, no. 4 (2019): 801–806.

[199] E. H. Buckarma, N. W. Werneburg, C. B. Conboy, et al., “The Yap-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma,” Molecular Cancer Research 18, no. 10 (2020): 1574–1588.

[200] R. Frankson, Z. H. Yu, Y. Bai, Q. Li, R. Y. Zhang, and Z. Y. Zhang, “Therapeutic Targeting of Oncogenic Tyrosine Phosphatases,” Cancer Research 77, no. 21 (2017): 5701–5705.

[201] M. Marasco, A. Berteotti, J. Weyershaeuser, et al., “Molecular Mechanism of SHP2 Activation by PD-1 Stimulation,” Science Advances 6, no. 5 (2020): eaay4458.

[202] C. M. Chio, C. S. Lim, and A. C. Bishop, “Targeting a Cryptic Allosteric Site for Selective Inhibition of the Oncogenic Protein Tyrosine Phosphatase Shp2,” Biochemistry 54, no. 2 (2015): 497–504.

[203] R. J. Nichols, F. Haderk, C. Stahlhut, et al., “Ras Nucleotide Cycling Underlies the SHP2 Phosphatase Dependence of Mutant BRAF-, NF1-and RAS-Driven Cancers,” Nature Cell Biology 20, no. 9 (2018): 1064–1073.

[204] T. Yokosuka, M. Takamatsu, W. Kobayashi-Imanishi, A. Hashimoto-Tane, M. Azuma, and T. Saito, “Programmed Cell Death 1 Forms Negative Costimulatory Microclusters That Directly Inhibit T Cell Receptor Signaling by Recruiting Phosphatase SHP2,” Journal of Experimental Medicine 209, no. 6 (2012): 1201–1217.

[205] K.-A. Sheppard, L. J. Fitz, J. M. Lee, et al., “Pd-1 Inhibits T-Cell Receptor Induced Phosphorylation of the ZAP70/CD3ζ Signalosome and Downstream Signaling to PKCθ,” FEBS Letters 574, no. 1/3 (2004): 37–41.

[206] Z. Song, M. Wang, Y. Ge, et al., “Tyrosine Phosphatase SHP2 Inhibitors in Tumor-Targeted Therapies,” Acta Pharmaceutica Sinica B 11, no. 1 (2021): 13–29.

[207] T. R. Wu, Y. K. Hong, X. D. Wang, et al., “SHP-2 Is a Dual-Specificity Phosphatase Involved in Stat1 Dephosphorylation at Both Tyrosine and Serine Residues in Nuclei,” Journal of Biological Chemistry 277, no. 49 (2002): 47572–47580.

[208] J. Xie, X. Si, S. Gu, et al., “Allosteric Inhibitors of SHP2 With Therapeutic Potential for Cancer Treatment,” Journal of Medicinal Chemistry 60, no. 24 (2017): 10205–10219.

[209] K. H. Tang, S. Li, A. Khodadadi-Jamayran, et al., “Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-Cell Response in NSCLC,” Cancer Discovery 12, no. 1 (2022): 47–61.

[210] E. Quintana, C. J. Schulze, D. R. Myers, et al., “Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment,” Cancer Research 80, no. 13 (2020): 2889–2902.

[211] X. Yang, Y. Zhang, Y. Zhang, et al., “The Key Role of Exosomes on the Pre-Metastatic Niche Formation in Tumors,” Frontiers in Molecular Biosciences 82 (2021): 703640.

[212] J. Gao, B. Wei, T. M. de Assuncao, et al., “Hepatic Stellate Cell Autophagy Inhibits Extracellular Vesicle Release to Attenuate Liver Fibrosis,” Journal of Hepatology 73, no. 5 (2020): 1144–1154.

[213] Z. Fan, Y. Tian, Z. Chen, et al., “Blocking Interaction Between SHP2 and PD-1 Denotes a Novel Opportunity for Developing PD-1 Inhibitors,” EMBO Molecular Medicine 12, no. 6 (2020): e11571.

[214] N. Krishnan, D. Koveal, D. H. Miller, et al., “Targeting the Disordered C Terminus of PTP1B With an Allosteric Inhibitor,” Nature Chemical Biology 10, no. 7 (2014): 558–566.

[215] H. A. Watson, S. Wehenkel, J. Matthews, and A. Ager, “SHP-1: The Next Checkpoint Target for Cancer Immunotherapy?,” Biochemical Society Transactions 44, no. 2 (2016): 356–362.

[216] W. S. Ho, M. J. Feldman, D. Maric, et al., “PP2A Inhibition With LB100 Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in Medulloblastoma Cells,” Oncotarget 7, no. 11 (2016): 12447–12463.

[217] W. Chien, Q. Y. Sun, K. L. Lee, et al., “Activation of Protein Phosphatase 2A Tumor Suppressor as Potential Treatment of Pancreatic Cancer,” Molecular Oncology 9, no. 4 (2015): 889–905.

[218] C. S. Hong, W. Ho, C. Zhang, C. Yang, J. B. Elder, and Z. Zhuang, “LB100, a Small Molecule Inhibitor of PP2A With Potent Chemo-and Radio-Sensitizing Potential,” Cancer Biology & Therapy 16, no. 6 (2015): 821–833.

[219] M. Thura, A. Q. O. Al-Aidaroos, W. P. Yong, et al., “PRL3-Zumab, a First-in-Class Humanized Antibody for Cancer Therapy,” JCI Insight 1, no. 9 (2016): e87607.

[220] D. R. Mattoon, B. Lamothe, I. Lax, and J. Schlessinger, “The Docking Protein Gab1 Is the Primary Mediator of EGF-Stimulated Activation of the PI-3K/Akt Cell Survival Pathway,” BMC Biology 2 (2004): 24.

[221] C. C. Chen, D. B. Hardy, and C. R. Mendelson, “Progesterone Receptor Inhibits Proliferation of Human Breast Cancer Cells via Induction of MAPK Phosphatase 1 (MKP-1/DUSP1),” Journal of Biological Chemistry 286, no. 50 (2011): 43091–43102.

[222] J. Fiebelkow, A. Guendel, B. Guendel, et al., “The Tyrosine Phosphatase SHP2 Increases Robustness and Information Transfer Within IL-6-Induced JAK/STAT Signalling,” Cell Communication and Signaling 19, no. 19 (2021): 94.

[223] C. Penafuerte, M. Feldhammer, J. R. Mills, et al., “Downregulation of PTP1B and TC-PTP Phosphatases Potentiate Dendritic Cell-Based Immunotherapy Through IL-12/IFNγ Signaling,” Oncoimmunology 6, no. 6 (2017): e1321185.

[224] T. Zhou, X. Li, J. Liu, and J. Hao, “The Hippo/YAP Signaling Pathway: The Driver of Cancer Metastasis,” Cancer Biology & Medicine 20, no. 7 (2023): 483–489.

[225] I. Baroja, N. C. Kyriakidis, G. Halder, and I. M. Moya, “Expected and Unexpected Effects After Systemic Inhibition of Hippo Transcriptional Output in Cancer,” Nature Communications 15, no. 1 (2024): 2700.

[226] D. Yang, N. Zhang, M. Li, T. Hong, W. Meng, and T. Ouyang, “The Hippo Signaling Pathway: The Trader of Tumor Microenvironment,” Frontiers in Oncology 11, no. 11 (2021): 772134.

[227] Z. Hu, J. Li, Q. Gao, S. Wei, and B. Yang, “SHP2 Overexpression Enhances the Invasion and Metastasis of Ovarian Cancer In Vitro and In Vivo,” OncoTargets and Therapy 10 (2017): 3881–3891.

[228] B. Zhao, X. Wei, W. Li, et al., “Inactivation of YAP Oncoprotein by the Hippo Pathway Is Involved in Cell Contact Inhibition and Tissue Growth Control,” Genes & Development 21, no. 21 (2007): 2747–2761.

[229] S.-W. Chen, S. Q. Zhu, X. Pei, et al., “Cancer Cell-Derived Exosomal circUSP7 Induces CD8+ T Cell Dysfunction and Anti-PD1 Resistance by Regulating the miR-934/SHP2 Axis in NSCLC,” Molecular Cancer 20, no. 1 (2021): 144.

[230] X. Li, K. M. Tran, K. E. Aziz, A. V. Sorokin, J. Chen, and W. Wang, “Defining the Protein-Protein Interaction Network of the Human Protein Tyrosine Phosphatase Family,” Molecular & Cellular Proteomics: MCP 15, no. 9 (2016): 3030–3044.

[231] N. J. Martinez, S. A. Titus, A. K. Wagner, and A. Simeonov, “High-Throughput Fluorescence Imaging Approaches for Drug Discovery Using In Vitro and In Vivo Three-Dimensional Models,” Expert Opinion on Drug Discovery 10, no. 12 (2015): 1347–1361.

[232] T. Etrych, H. Lucas, O. Janoušková, et al., “Fluorescence Optical Imaging in Anticancer Drug Delivery,” Journal of Controlled Release 226, no. 226 (2016): 168–181.

[233] M. Zheng, Y. Liu, C. Wu, et al., “Novel PROTACs for Degradation of SHP2 Protein,” Bioorganic Chemistry 110, no. 110 (2021): 104788.

[234] Z. Guo, Y. Duan, K. Sun, et al., “Advances in SHP2 Tunnel Allosteric Inhibitors and Bifunctional Molecules,” European Journal of Medicinal Chemistry 275 (2024): 116579.

[235] Y. Sun, B. A. Meyers, B. Czako, et al., “Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms Toward Osimertinib,” Cancer Research 80, no. 21 (2020): 4840–4853.

[236] S. M. Li, “The Biological Function of SHP2 in Human Disease,” Molecular Biology 50, no. 1 (2016): 22–27.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm - Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).